Le Lézard
Classified in: Science and technology, Business
Subjects: JVN, CXP

Ekinops Enables T-Mobile Czech Republic to Deliver Legacy and Virtual Services Across Single Operating System


PARIS, Nov. 12, 2019 /PRNewswire/ -- EKINOPS (Euronext Paris: EKI) (ISIN: FR0011466069), a leading provider of open, future-proof and fully flexible network solutions to service providers, today announces it has enabled T-Mobile Czech Republic (CZ) to streamline management across its part of product portfolio with the OneAccess branded OneOS6 operating system. The solution has enabled huge operational efficiencies in the delivery of T-Mobile CZ's traditional service portfolio.

Ekinops Logo

T-Mobile Czech Republic is the country's largest telco operator and part of the Deutsche Telekom group, delivering mobile and fix telecommunication, TV and ICT services to businesses and consumers.

Ekinops was selected because of its unrivalled range of fully open hardware and software. Now, the operator is equipped with a full set of carrier-grade business data routers, eventually supporting traditional voice ports and a virtualization platform that is able to service chain VNFs from both Ekinops and third parties as well as support future Ekinops Software-defined solutions.

Utilizing Ekinops' OneOS6 operating system across all OneAccess devices and x86-based universal CPE (uCPE), testing, maintenance and delivery of new services is dramatically simplified, while training and integration costs are reduced.

"Ekinops was the only supplier that could provide a single operating system capable of supporting all our technologies including data and voice," commented Michal Brcak Head of Product Management Enterprise at T-Mobile CZ. "Thanks to Ekinops' open system approach, we now have complete control over our technology choices. Thanks to OneOS6 we have also been able to reduce the training requirements for our technicians, and decrease costs associated with maintaining multiple operating systems."

"The OneOS6 implementation at T-Mobile reflects what Ekinops does best: deploy open systems that give operators both freedom and control, together with a host of cost saving and operational efficiency gains," commented Frank Dedobbeleer, VP Group Sales EMEA & APAC at Ekinops. "As operators continue their migration to software defined and virtualized services it's vital that they remain in charge of their destinies, defining the technology pathways and the pace of migration according to their own commercial plans. Like many operators, T-Mobile needs solutions that work in a hybrid physical/virtual environment for many years to come. Implementing open systems like OneOS6, that support both traditional and virtualized services, enable this journey by ensuring that migration can proceed without impeding the continued delivery of existing services"

More information on the OneAccess branded OneOS6 solutions can be found here.

For more information, visit www.ekinops.com 

Contact

For further media information, or to schedule an interview with Ekinops, please contact Lucie Rohani, iseepr 

+44 (0)113-350-1922 / lucie.r@iseepr.co.uk

SOURCE Ekinops


These press releases may also interest you

at 12:05
Stoke Therapeutics, Inc. , a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced preclinical data from studies of STK-001 that showed...

at 11:05
Aptose Biosciences Inc. released highlights from a corporate event and clinical update today held at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, FL. The event was hosted by the Aptose management team and...

at 11:00
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Resideo Technologies, Inc. between October 10, 2018 and October 22, 2019, inclusive (the "Class Period") of the important January 7, 2020 lead plaintiff...

at 10:25
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today initial results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-68284528 (JNJ-4528), an investigational B cell maturation antigen...

at 10:20
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced combination data from two studies and a long-term integrated analysis evaluating the use of Imbruvica® (ibrutinib) for the treatment of previously untreated patients with CLL....

at 10:10
Epizyme, Inc. , a late-stage biopharmaceutical company developing novel epigenetic therapies, today reported positive, mature data at the 2019 American Society of Hematology (ASH) Annual Meeting from its ongoing Phase 2 trial of tazemetostat, an oral...



News published on 12 november 2019 at 13:00 and distributed by: